Intercept Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Intercept Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date Intercept Pharmaceuticals Inc Strategy Report
- Understand Intercept Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Intercept Pharmaceuticals Inc (Intercept), a subsidiary of Alfasigma SpA, is a biopharmaceutical company that researches, develops, and commercializes treatments for non-viral, progressive liver diseases. It develops products using proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company is advancing OCA for the treatment of primary biliary cholangitis (PBC) and other liver diseases. The company harnesses its proprietary bile acid chemistry to develop innovative drugs. It is also advancing INT-787, an FXR agonist for the treatment of severe alcohol-associated hepatitis and obeticholic acid (OCA) and bezafibrate for the potential treatment of individuals with PBC. Intercept is headquartered in Morristown, New Jersey, the US.
Intercept Pharmaceuticals Inc premium industry data and analytics
Products and Services
Products |
---|
- |
Marketed |
Ocaliva (Obeticholic Acid): Primary Biliary Cholangitis (PBC) |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Acquisitions/Mergers/Takeovers | In November, the company got acquired by Alfasigma S.p.A. |
2023 | Regulatory Approval | In May, the company announced that the U.S. Food and Drug Administration granted orphan drug designation for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate for the potential treatment of individuals with primary biliary cholangitis (PBC). |
2023 | Others | In March, the company announced FDA Advisory Committee meeting date for obeticholic acid as a treatment for pre-cirrhotic liver fibrosis to be held virtually. |
Competitor Comparison
Key Parameters | Intercept Pharmaceuticals Inc | Novartis AG | AstraZeneca Plc | Bristol-Myers Squibb Co | Novo Nordisk AS |
---|---|---|---|---|---|
Headquarters | United States of America | Switzerland | United Kingdom | United States of America | Denmark |
City | Morristown | Basel | Cambridge | Princeton | Bagsvaerd |
State/Province | New Jersey | - | England | New Jersey | - |
No. of Employees | 341 | 76,057 | 89,900 | 34,100 | 63,370 |
Entity Type | Private | Public | Public | Public | Public |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Vivek Devaraj | Chairman; President - U.S. | Executive Board | - | - |
Rocco Venezia | Chief Financial Officer | Senior Management | 2023 | - |
Kathleen Munster | Senior Vice President - Technical Operations; Chief Quality Officer | Senior Management | - | - |
Sangeeta Sawhney | Head - U.S. Research and Development; Senior Vice President | Senior Management | - | - |
Richard Johnson | Senior Vice President; Head - U.S. Human Resources | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer